GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alkermes PLC (STU:8AK) » Definitions » Research & Development

Alkermes (STU:8AK) Research & Development : €227 Mil (TTM As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Alkermes Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Alkermes's Research & Development for the three months ended in Mar. 2024 was €62 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was €227 Mil.

Alkermes Research & Development Historical Data

The historical data trend for Alkermes's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alkermes Research & Development Chart

Alkermes Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 461.55 324.35 257.47 257.43 248.33

Alkermes Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 59.56 93.03 91.02 -19.04 62.20

Alkermes Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €227 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alkermes  (STU:8AK) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Alkermes Research & Development Related Terms

Thank you for viewing the detailed overview of Alkermes's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Alkermes (STU:8AK) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alkermes PLC (STU:8AK) » Definitions » Research & Development
Comparable Companies
PRGO ALVO LNTH PBH AMPH AMRX ELAN SUPN AVDL TARO ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ VTRS SZSE:000538 NBIX
Traded in Other Exchanges
ALKS:USA 8AK:Germany
Address
1 Burlington Road, Connaught House, Dublin, IRL, D04 C5Y6
Website
https://www.alkermes.com
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.

Alkermes (STU:8AK) Headlines

No Headlines